Enzamide 40mg Capsule contains Enzalutamide, a nonsteroidal antiandrogen agent indicated primarily for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Enzalutamide functions by inhibiting androgen receptor signaling, thereby preventing androgen receptor nuclear translocation, DNA binding, and coactivator recruitment, which are critical processes in prostate cancer cell proliferation and survival. This therapeutic agent is administered orally and is typically prescribed as part of a comprehensive treatment regimen for patients with advanced prostate cancer who have shown resistance to conventional androgen deprivation therapy. Enzamide 40mg Capsule has demonstrated efficacy in delaying disease progression, reducing tumor burden, and improving overall survival rates. The medication should be used under strict medical supervision, with dosage adjustments based on clinical response and tolerability. Common adverse effects may include fatigue, hypertension, hot flashes, and gastrointestinal disturbances, while rare but serious risks include seizures and cardiovascular events. Regular monitoring of liver function, blood pressure, and neurological status is recommended during treatment. Enzamide is contraindicated in patients with hypersensitivity to Enzalutamide or its excipients. This capsule formulation offers a convenient dosing option, facilitating adherence to long-term therapy in the management of advanced prostate cancer.